Publications by authors named "Kyle H Bond"
Clinical association studies suggest that FOXD1 is a determinant of patient outcome in clear cell renal cell carcinoma (ccRCC), and laboratory investigations have defined a role for this transcription factor in controlling the growth of tumors through regulation of the G2/M cell cycle transition. We hypothesized that the identification of pathways downstream of FOXD1 may define candidates for pharmacological modulation to suppress the G2/M transition in ccRCC. We developed an analysis pipeline that utilizes RNA sequencing, transcription factor binding site analysis, and phenotype validation to identify candidate effectors downstream from FOXD1.
View Article and Find Full Text PDFArticle Synopsis
- Clear cell renal cell carcinoma (ccRCC) is the most prevalent type of kidney cancer, primarily triggered by mutations affecting oxygen sensing in kidney cells.
- Current lab techniques fall short in replicating the diverse environment of ccRCC tumors, which leads to a need for improved models to study both tumor and supporting stromal cells.
- The study identified a unique extracellular matrix (ECM) composition in ccRCC, mainly consisting of collagen VI, fibronectin, and tenascin C, and developed a nine-component ECM blend that enables the growth of both tumor and stromal cells for better modeling and analysis of cell interactions in a tumor-like setting.
Background: Forkhead transcription factors control cell growth in multiple cancer types. Foxd1 is essential for kidney development and mitochondrial metabolism, but its significance in renal cell carcinoma (ccRCC) has not been reported.
Methods: Transcriptome data from the TCGA database was used to correlate FOXD1 expression with patient survival.